CRISPR Therapeutics AG（CRSP）股票分析CRSPCRISPR Therapeutics AG

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

CRISPR Therapeutics AG (CRSP) is currently a good buy at $49.39, especially considering its recent positive developments such as a 151% year-over-year increase in Casgevy revenue and Cathie Wood's significant stock purchases totaling $3.4 million. The stock has a forward P/E of 23.36, indicating growth potential, despite a current RSI of 36.26 suggesting it is oversold. The main risk is the company's ongoing net losses, which reached -$91.15 million in Q2 2026, highlighting the need for careful monitoring of its financial recovery.

6 analysts cover CRSP: 3 rate it Buy, 3 Hold and 0 Sell. The average price target is 78.89.